32 results
10-Q
2024 Q1
CHRO
Chromocell Therapeutics Corp.
15 May 24
Quarterly report
4:06pm
For the Three Months Ended | For the Three Months Ended | |||||||
March 31, 2024 | March 31, 2023 | |||||||
OPERATING EXPENSES | ||||||||
General and administrative expenses | $ | 787,561 | $ | 477,630 | ||||
Research and development | 466,606 | 186,117 | ||||||
Professional fees | 679,815 | 250,836 | ||||||
Total operating expenses | 1,933,982 | 914,583 | ||||||
NET LOSS FROM OPERATIONS | (1,933,982) | (914,583) | ||||||
OTHER (EXPENSE) INCOME | ||||||||
Interest expense | (628,348) | (51,978) | ||||||
Total other (expense) income | (628,348) | (51,978) | ||||||
Net loss before provision for income taxes | (2,562,330) | (966,561) | ||||||
Provision for income taxes | — | — | ||||||
NET LOSS | $ | (2,562,330) | $ | (966,561) | ||||
Net loss per common share - basic and diluted | $ | (0.55) | $ | (0.87) | ||||
Weighted average number of common shares outstanding during the year - basic and diluted | 4,690,989 | 1,111,112 |
10-Q
2024 Q1
CHRO
Chromocell Therapeutics Corp.
15 May 24
Quarterly report
4:06pm
For the Three Months Ended March 31, 2024 | For the Three Months Ended March 31, 2023 | $ Change | % Change | |||||||||||||
OPERATING EXPENSES | ||||||||||||||||
General and administrative expenses | $ | 787,561 | $ | 477,630 | $ | 309,931 | 65 | % | ||||||||
Research and development | 466,606 | 186,117 | 280,489 | 151 | % | |||||||||||
Professional fees | 679,815 | 250,836 | 428,979 | 171 | % | |||||||||||
Total operating expenses | 1,933,982 | 914,583 | 1,019,399 | 111 | % | |||||||||||
Loss from operations | (1,933,982) | (914,583) | (1,019,399) | (111 | )% | |||||||||||
Other expense | (628,348) | (51,978) | (576,370) | 1,109 | % | |||||||||||
Net loss before provision for income taxes | (2,562,330) | (966,561) | (1,595,769) | 165 | % | |||||||||||
Provision for income taxes | — | — | — | NA | ||||||||||||
Net loss | $ | (2,562,330) | $ | (966,561) | $ | (1,595,769) | 165 | % |
10-K
2023 FY
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Annual report
4:48pm
For the Year Ended December 31, 2023 | For the Year Ended December 31, 2022 | $ Change | % Change | |||||||||||||
OPERATING EXPENSES | ||||||||||||||||
General and administrative expenses | $ | 2,738,948 | $ | 1,098,848 | $ | 1,640,100 | 149 | % | ||||||||
Research and development | 2,579,418 | 391,730 | 2,187,688 | 558 | % | |||||||||||
Professional fees | 1,543,918 | 827,581 | 716,337 | 87 | % | |||||||||||
Total operating expenses | 6,862,284 | 2,318,159 | 4,544,125 | 196 | % | |||||||||||
Loss from operations | (6,862,284) | (2,318,159) | (4,544,125) | (196 | )% | |||||||||||
Other expense | (518,509) | (140,430) | (378,079) | 269 | % | |||||||||||
Net loss before provision for income taxes | (7,380,793) | (2,458,859) | (4,922,204) | 200 | % | |||||||||||
Provision for income taxes | — | — | — | NA | ||||||||||||
Net loss | $ | (7,380,793) | $ | (2,458,589) | $ | (4,922,204) | 200 | % |
10-K
2023 FY
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Annual report
4:48pm
STATEMENTS OF OPERATIONS
For the Year Ended | For the Year Ended | |||||||
December 31, 2023 | December 31, 2022 | |||||||
OPERATING EXPENSES | ||||||||
General and administrative expenses | $ | 2,738,948 | $ | 1,098,848 | ||||
Research and development | 2,579,418 | 391,730 | ||||||
Professional fees | 1,543,918 | 827,581 | ||||||
Total operating expenses | 6,862,284 | 2,318,159 | ||||||
NET LOSS FROM OPERATIONS | (6,862,284) | (2,318,159) | ||||||
OTHER (EXPENSE) INCOME | ||||||||
Interest expense | (518,509) | (140,430) | ||||||
Total other (expense) income | (518,509) | (140,430) | ||||||
Net loss before provision for income taxes | (7,380,793) | (2,458,589) | ||||||
Provision for income taxes | — | — | ||||||
NET LOSS | $ | (7,380,793) | $ | (2,458,589) | ||||
Net loss per common share - basic and diluted | $ | 5,78 | ) | $ | 5,65 | ) | ||
Weighted average number of common shares outstanding during the year - basic and diluted | 1,276,543 | 435,312 |